Insights about U.S. Stocks that landed in the Green-Zone during Thursday’s trade, are depicted underneath:
CTI BioPharma Corp (NASDAQ:CTIC)’s shares picked up 10.57%, and closed at $2.72.
CTI BioPharma Corp. (CTIC), declared that it plans to report its fourth quarter and full year 2014 financial results on Thursday, March 12, 2015, after the close of the U.S. financial markets. Following the declaration, members of the administration team will host a webcast conference call to talk about the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT).
CTI BioPharma Corp. (NASDAQ:CTIC) is a biopharmaceutical corporation focused on the attainment, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers.
Heron Therapeutics Inc (NASDAQ:HRTX), raised 10.34%, and closed at $15.47, hitting new 52-week high of $15.86.
Heron Therapeutics, Inc. (HRTX), a biotechnology corporation, declared that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the following conferences in March 2015:
27th Annual ROTH Conference in Laguna Niguel, CA. Presentation: Monday, March 9, 2015 at 4:30 p.m. ET (1:30 p.m. PT).
Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc.) is a biotechnology corporation using its proprietary technology and innovative efforts to develop products to address unmet medical needs. The Corporation’s proprietary Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action of known active ingredients.
Receptos Inc (NASDAQ:RCPT), enhanced 10.30%, and closed at $141.19, hitting new 52-week high of $143.05.
Receptos, Inc. (RCPT), a biopharmaceutical corporation developing therapeutic candidates for the treatment of immune and metabolic diseases, recently offered development program updates and reviewed financial results for the fourth quarter and year ended December 31, 2014.
Development Program Updates:
Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (RMS)
After reporting positive results in the Phase 2 portion of the RADIANCE trial of ozanimod in RMS, Receptos initiated the second Phase 3 trial of ozanimod in RMS, called SUNBEAM. Similar to the RADIANCE Phase 3 trial, the SUNBEAM trial is a randomized, double-blind study designed to compare 0.5 mg and 1.0 mg of ozanimod against interferon beta-1a (Avonex(R)) in about 1,200 patients with RMS. The primary objectives of the RADIANCE and SUNBEAM trials are to assess whether ozanimod is superior to Avonex(R) in reducing the annualized relapse rate in patients after two years of therapy and one year of therapy, respectively. Both Phase 3 trials are being conducted under Special Protocol Assessment (SPA) contract with the FDA.
Receptos is a biopharmaceutical corporation developing therapeutic candidates for the treatment of immune and metabolic diseases. The Corporation’s lead program, ozanimod, is a sphingosine 1-phosphate 1 and 5 receptor small molecule modulator in development for immune indications counting RMS and IBD.
Pharmacyclics, Inc (NASDAQ:PCYC), rose 10.30%, and closed at $254.22, hitting new 52-week high of $255.52.
Formerly on February 27, Pharmacyclics Inc. (PCYC), declared that longer-term toxicology studies for its newly developed Bruton’s tyrosine kinase (BTK) inhibitor for rheumatoid arthritis, or RA, have been accomplished. The results of these preclinical evaluations have been communicated to the U.S. Food and Drug Administration. The feedback received from the Agency is supportive of the completion of the ongoing first-in-human study. Additional preclinical work is required to start a Phase II clinical development program in autoimmune diseases with this investigational compound. The Corporation does not anticipate initiating a Phase II study until additional preclinical work is successfully accomplished. Further updates on the progress of these efforts will be offered when appropriate.
Pharmacyclics, Inc. (PCYC) is a biopharmaceutical corporation focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. The corporation’s mission is to build a viable biopharmaceutical corporation that designs, develops and commercializes novel therapies intended to improve quality of life, raise duration of life and resolve serious unmet medical needs. It will do so by identifying and controlling promising product candidates based on scientific development and administrative expertise, developing its products in a rapid, cost-efficient manner and, pursuing commercialization and/or development partners when and where appropriate.
